Drug Profile
ADR 001
Alternative Names: ADR-001Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Rohto Pharmaceutical
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II COVID-19 pneumonia
- Phase I/II Liver cirrhosis
- No development reported IgA nephropathy
Most Recent Events
- 28 Nov 2023 Rohto Pharmaceutical completes a phase II trial in COVID-19 pneumonia in Japan (NCT04888949)
- 28 Jul 2023 No recent reports of development identified for phase-I development in IgA-nephropathy in Japan (IV, Infusion)
- 18 Jul 2023 Rohto Pharmaceutical completes a phase I/II trial in Cirrhosis in Japan (IV) (NCT03254758)